Navigation Links
Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Date:11/6/2007

In Phase I Clinical Evaluation Anticoagulant Inhibits Clotting Factor IXa;

Matched Antidote Rapidly Reverses Anticoagulant Effect

ORLANDO, Fla., Nov. 6 /PRNewswire/ -- Regado Biosciences today presented encouraging data from Phase Ia and Phase Ib dose escalation studies of the Company's REG1 Anticoagulation System. REG1 is a two-component system consisting of an aptamer-based anticoagulant, RB006, and its matched antidote, RB007, which binds to and neutralizes RB006. The data showed RB006 completely inhibited the activity of Factor IXa, a protein essential to blood clotting, and RB006's activity was rapidly and safely reversed by RB007 in the Phase I studies. Confirming previously reported Phase I results, these data were presented at the American Heart Association's 2007 Scientific Sessions, currently being held in Orlando, Florida.

"These Phase I results are encouraging, and this system should be evaluated further in confirmatory Phase II and III clinical studies. Experienced clinicians recognize the importance of being able to titrate the intensity of anticoagulation according to specific patient needs. Current drugs do not offer an optimal level of control or flexibility," said Richard C. Becker, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute. "Should additional well-controlled clinical studies confirm these data, REG1 may have potential for broad applications in clinical practice settings from the emergency room to the operating room."

Scientists from the Duke Clinical Research Institute and Regado analyzed REG1 pharmacokinetics and dosing data from 134 subjects enrolled in two of the three Phase I studies. The Phase Ia study enrolled 84 healthy volunteers; the Phase Ib study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results of the analysis showed an int
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... TARRYTOWN, N.Y. , May 23, 2013 /PRNewswire/ ... reconstruction following mastectomy is an appropriate option ... mutations seeking to surgically reduce their breast cancer ... involves a gradual expansion process and a second ... of implants in the same surgery as mastectomy ...
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
(Date:5/23/2013)... 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ... the development and commercialization of novel bile acid therapeutics ... cirrhosis, today announced that Mark Pruzanski ... at the Deutsche Bank Securities 38th Annual Health Care ... May 29, 2013 at 4:10 p.m. ET. ...
Breaking Medicine Technology:Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... 3, 2011 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... $111.2 million, a 17 percent increase over revenues of ... Results for all periods of fiscal 2010 exclude ...
... IRVINE, Calif., Aug. 3, 2011 Endologix, Inc. ... of minimally invasive treatments for aortic disorders, announced ... Officer, is scheduled to present at two upcoming ... the 31st Annual Canaccord Genuity Growth Conference in ...
Cached Medicine Technology:Thoratec Reports Second Quarter Revenue Increase of 17 Percent 2Thoratec Reports Second Quarter Revenue Increase of 17 Percent 3Thoratec Reports Second Quarter Revenue Increase of 17 Percent 4Thoratec Reports Second Quarter Revenue Increase of 17 Percent 5Thoratec Reports Second Quarter Revenue Increase of 17 Percent 6Thoratec Reports Second Quarter Revenue Increase of 17 Percent 7Thoratec Reports Second Quarter Revenue Increase of 17 Percent 8Thoratec Reports Second Quarter Revenue Increase of 17 Percent 9Thoratec Reports Second Quarter Revenue Increase of 17 Percent 10Thoratec Reports Second Quarter Revenue Increase of 17 Percent 11Thoratec Reports Second Quarter Revenue Increase of 17 Percent 12Thoratec Reports Second Quarter Revenue Increase of 17 Percent 13Thoratec Reports Second Quarter Revenue Increase of 17 Percent 14Thoratec Reports Second Quarter Revenue Increase of 17 Percent 15Thoratec Reports Second Quarter Revenue Increase of 17 Percent 16Thoratec Reports Second Quarter Revenue Increase of 17 Percent 17Thoratec Reports Second Quarter Revenue Increase of 17 Percent 18Thoratec Reports Second Quarter Revenue Increase of 17 Percent 19Endologix to Present at Two Upcoming Conferences 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 HCG EZ Drops ... and is excited to announce it’s new weight loss initiative. “We ... we are offering our customers their money back if they don’t ... CEO of HCG EZ Drops. “The HCG Diet consists of ... the 21 pounds in 21 days.” , The controversial, cutting-edge diet ...
(Date:5/24/2013)... The leading retail brand Short Dresses ... prom dresses . Now that is quite unbelievable, especially in ... brand name since its origin. The retailer has already revealed ... this huge discount offer will be an added bonanza for ... privileged to announce that Short Dresses is to offer different ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Over the ... been gradually transforming, which has affected the Medical ... debt and seeking regular hours, more young physicians are ... or other medical groups,” says IBISWorld industry analyst Anna ... reimbursement pressure, a number of older physicians are selling ...
(Date:5/23/2013)... High blood glucose is associated with poor outcomes in ... to control hyperglycemia is a common practice in hospitals. ... benefit and even shows harms associated with the use ... (ACP) Clinical Guidelines Committee in a new evidence-based paper ... Medical Quality . , "Clinicians caring for hospitalized patients ...
(Date:5/23/2013)... 2013 The sodium theory ... and B. Katz in the early 1950s, after their ... of sodium and potassium ions in nerve functions ... acquisition techniques have known amazing developments. In The Sodium ... give an account of the latest developments in the ...
Breaking Medicine News(10 mins):Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3
... The Journal of the American Dental Association ... in publishing a global theme issue on poverty ... the worlds biomedical publications., The Council of Science ... simultaneous publication by science journals throughout the world ...
... Medical Center may have solved the mystery surrounding the healing ... interest in gold salts as a treatment for rheumatoid arthritis ... gold salts in the early 1900s to ease the pain ... a high cost: The shots took months to take ...
... Sponsored by Health Improvement Institute, Consumer,Reports WebWatch, ... is organizing a one-day workshop Monday, November 12,to ... Internet., Held at the Hyatt Regency Hotel ... health experts, representatives of relevant,organizations, and consumers to ...
... Pre-Emption in Riegel v. Medtronic, Inc., WASHINGTON, Oct. ... Medical Technology Association,(AdvaMed) filed a joint amicus brief Friday ... v. Medtronic, Inc. arguing that the FDA should,continue to ... states that,no other legislative or regulatory entity is better ...
... J. Halamandaris,President of the National Association for Home Care ... the power of caring, both at home,and in their ... Hospice Month., "It is highly appropriate that we ... nurses, therapists, aides and other providers who have chosen,to ...
... publisher, is proud to be participating in a Global ... by the Council of Science Editors. , The CSE ... interest and debate on the crucial matters of poverty ... developed and developing countries will simultaneously publish papers on ...
Cached Medicine News:Health News:Journal of the American Dental Association spotlights poverty 2Health News:Scientists discover how gold eases pain of arthritis 2Health News:Can the Web Transform the U.S. Healthcare System? 2Health News:Can the Web Transform the U.S. Healthcare System? 3Health News:Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc. 2Health News:U.S. Celebrates National Home Care and Hospice Month in November 2Health News:9 SAGE journals participate in global theme issue on poverty and human development 2
... for the semi-quantitative determination of specific IgA ... results of the anti-Gliadin IgA assay can ... diagnosis of diseases associated with elevated levels ... of these autoantibodies are one indicator in ...
... The Urisys 1800 System is the proper ... urinalysis workload in a convenient and efficient ... designed for optimized work and data flow, ... terminal.Fast processing of test strips accelerates analysis ...
... (E3) is one of the 3 major ... and estrone). In terms of estrogenic activity, ... [1]. Estriol is produced almost exclusively during ... in the normal human fetus. During pregnancy, ...
Direct assays, no sample extraction, hydrolysis or other pretreatment required. Highly specific antiserum, minimal cross-reactivity with estrone, estradiol and other estrogen metabolites....
Medicine Products: